ArticleThe Lancet. Microbe2025

Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.

Nicola Borthwick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.